19,113
Participants
Start Date
January 7, 2020
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2022
Proactive Outreach
"The treatment is proactive outreach that sought to enroll individuals in a VBID program available to all enrollees that provided: 1) large reductions in cost-sharing for maintenance inhalers, and 2) telephone-based COPD medication management services.~Proactive outreach for those randomized to the treatment arm included, at a minimum, a phone call and letter in the mail from Humana. Proactive outreach could also have included an email, text message, and/or provider referral."
No Proactive Outreach
Control group participants received no proactive outreach but could call to enroll themselves in the VBID program if they learned about it through traditional means, such as the benefits description manual.
Humana, Inc., Louisville
University of Chicago, Chicago
Harvard Medical School, Boston
Humana Co.Ltd.
INDUSTRY
Harvard Medical School (HMS and HSDM)
OTHER